Eucalyptus Bio Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4M

  • Investors
  • 7

Eucalyptus Bio General Information

Description

Operator of a clinical company intended to develop gene editing technology for rare diseases. The company's platform directs cells to use error-free rather than error-prone pathways that decrease cellular toxicity to leverage strategic advantage with large edits to develop genetic cures for liver and pancreatic diseases in-house, enabling medical researchers to overcome issues regarding editing genomic deoxyribonucleic acid for therapeutic applications via manipulation of the target cell's repair pathways.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 930 Brittan Avenue
  • San Carlos, CA 94070
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 930 Brittan Avenue
  • San Carlos, CA 94070
  • United States
+1 (415)

Eucalyptus Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eucalyptus Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 08-Jan-2024 $4M Completed Pre-Clinical Trials
5. Accelerator/Incubator 13-Oct-2023 Completed Pre-Clinical Trials
4. Early Stage VC 14-Sep-2023 Completed Product In Beta Test
3. Accelerator/Incubator 20-Mar-2022 Completed Startup
2. Early Stage VC 16-Mar-2022 $1.25M $1.58M Completed Startup
1. Early Stage VC 01-Aug-2021 $330K $330K Completed Startup
To view Eucalyptus Bio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Eucalyptus Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical company intended to develop gene editing technology for rare diseases. The company's platform dir
Drug Discovery
San Carlos, CA
3 As of 2024

Cambridge, MA
 

Zug, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eucalyptus Bio Competitors (5)

One of Eucalyptus Bio’s 5 competitors is Prime Medicine, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prime Medicine Formerly VC-backed Cambridge, MA
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
Editas Medicine Formerly VC-backed Cambridge, MA
Ascidian Venture Capital-Backed Boston, MA
Beam Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 5 competitors. Get the full list »

Eucalyptus Bio Patents

Eucalyptus Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023168235-A2 Systems and methods of gene editing Inactive 01-Mar-2022
WO-2023168235-A3 Systems and methods of gene editing Inactive 01-Mar-2022
EP-4199956-A2 A nuclease and application thereof Inactive 24-Aug-2020
WO-2022046669-A2 A nuclease and application thereof Inactive 24-Aug-2020
WO-2022046669-A3 A nuclease and application thereof Inactive 24-Aug-2020 C12N15/1135
To view Eucalyptus Bio’s complete patent history, request access »

Eucalyptus Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eucalyptus Bio Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Endless Frontier Labs Accelerator/Incubator
Illumina Accelerator Accelerator/Incubator Minority
University of California, Santa Barbara University Minority
GCAIA Capital Angel Group Minority
MIT Alumni Angels of Northern California Angel Group Minority
You’re viewing 5 of 7 investors. Get the full list »

Eucalyptus Bio FAQs

  • When was Eucalyptus Bio founded?

    Eucalyptus Bio was founded in 2019.

  • Where is Eucalyptus Bio headquartered?

    Eucalyptus Bio is headquartered in San Carlos, CA.

  • What is the size of Eucalyptus Bio?

    Eucalyptus Bio has 3 total employees.

  • What industry is Eucalyptus Bio in?

    Eucalyptus Bio’s primary industry is Drug Discovery.

  • Is Eucalyptus Bio a private or public company?

    Eucalyptus Bio is a Private company.

  • What is Eucalyptus Bio’s current revenue?

    The current revenue for Eucalyptus Bio is .

  • How much funding has Eucalyptus Bio raised over time?

    Eucalyptus Bio has raised $6.03M.

  • Who are Eucalyptus Bio’s investors?

    Endless Frontier Labs, Illumina Accelerator, University of California, Santa Barbara, GCAIA Capital, and MIT Alumni Angels of Northern California are 5 of 7 investors who have invested in Eucalyptus Bio.

  • Who are Eucalyptus Bio’s competitors?

    Prime Medicine, CRISPR Therapeutics, Editas Medicine, Ascidian, and Beam Therapeutics are competitors of Eucalyptus Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process